During Tuesday’s Afternoon trade, Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), gained 1.78% to $0.0917.
Aeterna Zentaris, declared that its lead oncology compound, zoptarelin doxorubicin (formerly AEZS‑108), met the primary end-point of the investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.
Results were presented this morning by lead investigator, Jacek Pinski , MD, PhD, of the USC Norris Comprehensive Cancer Center, during a poster session at the 18th ECCO – 40th ESMO European Cancer Congress in Vienna, Austria.
On other hand, AEterna Zentaris (AEZS)‘s stock had its “buy” rating reissued by investment analysts at Maxim Group in a research note issued to investors on Monday, Analyst Ratings Network.com reports. They presently have a $2.00 target price on the biopharmaceutical company’s stock.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Shares of Baxter International Inc (NYSE:BAX), declined -2.10% to $32.58, during its current trading session.
Baxter International, will host a quarterly conference call to discuss its third quarter 2015 financial results on Tuesday, October 27, 2015, at 7:30 a.m. central time.
On other hand, Shares of Baxter International (BAX) have been given an average rating of “Hold” by the fifteen brokerages that are presently covering the company, Market Beat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $50.92.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Shares of News Corp (NASDAQ:NWSA), climbed 2.84%, and is now trading at $15.84.
Realtor.com, a leading provider of online real estate services operated by News Corp partner Move, Inc. declared that its original five-episode, digital video series, featuring actress Elizabeth Banks, providing practical, humorous advice to first-time home buyers, has won five digital advertising awards.
The campaign received top honors from advertising trade publication Mediapost’s Online Marketing Media and Advertising (OMMA) awards for its Use of Humor in the category of Online Advertising Creativity. The realtor.com campaign also was honored with two Gold and two Silver Awards by W3 for Branded Content: Business to Consumer; Video Features: Individual Performance; Online Video: Web Series; and Microsite: Real Estate, respectively.
News Corporation, a media and information services company, focuses on creating and distributing content to consumers and businesses worldwide. The company distributes content and data products, such as The Wall Street Journal, Factiva, Dow Jones Risk & Compliance, Dow Jones Newswires, Barron’s, MarketWatch, Dow Jones Private Markets, and DJX through various media channels, counting newspapers, newswires, Websites, newsletters, magazines, proprietary databases, conferences, and video, in addition to applications for mobile devices, tablets, and electronic readers.
Finally, Shares of Cousins Properties Inc (NYSE:CUZ), gained 0.86%, and is now trading at $9.37.
Cousins Properties Incorporated, declared that it will release third quarter earnings after the market closes on Tuesday, October 27, 2015. Cousins invites you to take part in its Third Quarter 2015 Conference Call Wednesday, October 28, 2015 at 11 a.m. (Eastern Time). The number to call for this teleconference is (877) 247-1056. A 14-day playback will start at 1:00 p.m. (Eastern Time) on Wednesday, October 28, 2015 and run through Wednesday, November 11, 2015.
On other hand, Cousins Properties (NYSE:CUZ) has been assigned a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, ARN reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $13.00.
Cousins Properties Incorporated, a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, in addition to performs certain real estate-related services in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
